A Phase II Study of Sacituzumab Govitecan in Combination With Cetuximab in Patients With Recurrent Metastatic HNSCC That Has Progressed After First-Line Therapy

Inclusion Criteria: * Pathologically (histologically or cytologically) proven diagnosis of squamous cell carcinoma of the head and neck arising from the sinuses, nasal cavity, oral cavity, oropharynx, hypopharynx, and larynx. Other sites not listed will be subject to PI discretion. * Advanced disease (Stage IV or M1 disease) not amenable to curative local therapy with surgery and/or radiation based approaches * Progression on first line anti-PD(L)1 therapy with or without chemotherapy or as part of a combination in a clinical trial * HPV status for oropharynx primary must be previously…